EAElif Ilgaz Aydinlar

Elif Ilgaz Aydinlar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elif Ilgaz Aydinlar has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Machine Learning Classification of Migraine Using fNIRS During a Postural Task

    by Emre Yorgancigil, Gülnaz Yükselen, Roksi Franci, Erkan Acar, Elif Ilgaz Aydinlar, Pinar Yalinay Dikmen, Ugur Uygunoglu, Aksel Siva, Abdullah Arcan, Feride Irem Simsek, et al.

    Background: Migraine diagnosis and severity staging rest on clinical interviews according to the ICHD-3 criteria, with no validated objective biomarker. Functional near-infrared spectroscopy (fNIRS) is a portable and non-invasive method, but existing fNIRS migraine classification studies remain relatively small and rely on cognitive tasks. We assessed whether prefrontal hemodynamic responses with a head-down-to-knees maneuver separate migraine patients from controls, and high- from low-severity migraine. Methods: Prefrontal fNIRS, including short separation channels, was recorded during the maneuver in 50 interictal migraine patients and 52 controls screened for the absence of migraine, serious chronic conditions and hypertension. Nine hemodynamic parameters per chromophore (HbO, Hb and HbT) across thirty channels entered a hypothesis-neutral pipeline of 270 candidate pipelines (3 chromophores × 3 feature selection strategies × 30 classifiers) with no predefined region of interest. Results: Deoxyhemoglobin features selected by embedded L1 regularization with shrinkage-regularized linear discriminant analysis separated the groups with 92% balanced accuracy on the internal hold-out (92% sensitivity, 92% specificity, ROC-AUC 0.99; permutation p = 3 × 10−4), against 87% in development-set cross-validation and 88% under nested selection cross-validation, with a selection bias of +0.03. High- vs. low-severity classification (19 high, 31 low) did not exceed chance under nested validation (45%; permutation p = 0.45). Conclusions: A wide-scale pipeline achieved a robust, validated separation of migraine from screened controls, carried by a distributed venous-weighted deoxyhemoglobin signature; specificity against other headache disorders remains to be established. Attack frequency severity was not separable above chance, indicating that scalar hemodynamic descriptors are sufficient for a categorical but not a graded contrast.

  • Open Access

    Clinical improvement of photophobia with galcanezumab in episodic and chronic migraine

    by Elif Ilgaz Aydınlar, Pınar Yalınay Dikmen, Aysenur Sahin, Kerem Birısık

    Objective: This study aimed to evaluate changes in photophobia using the Turkish version of Utah Photophobia Symptom Impact Scale–12 (UPSIS-12) in patients with episodic (EM) and chronic migraine (CM) treated with galcanezumab, and to examine the relationship between photophobia, migraine outcomes, disability, and treatment response. Background: Photophobia is one of the most bothersome symptoms (MBS) of migraine and may persist during both ictal and interictal periods, leading to substantial impairment in daily functioning. Despite the clear clinical relevance of photophobia, the specific effects of galcanezumab, a CGRP monoclonal antibody, on photophobia have not yet been fully elucidated. Methods: This retrospective study, included patients with EM and CM treated with galcanezumab (240 mg loading dose followed by monthly 120 mg) for 3 months. Patients completed headache diaries and validated patient-reported outcome measures (PROMs) at baseline and monthly follow-up visits. Non-parametric tests, correlation analyses, and multivariable linear regression were performed. Results: A total of 77 patients were enrolled, of whom 47 (89.3% female; mean age 39.5 ± 10.6 years) completed all study visits and were included in the final analysis. Over the study period, monthly headache days (MHDs) decreased from a median of 15 to 4 days by month 3 ( p < 0.001), with 74.5% of patients classified as responders (≥50% reduction). UPSIS-12 scores declined significant (median 22.6%; p < 0.001). Although baseline UPSIS-12 scores were similar between responders and non-responders, responders demonstrated a notable reduction in ictal photophobia ( p = 0.010). Significant improvements were also observed in ictal phonophobia, osmophobia, and cutaneous allodynia, whereas interictal sensory symptoms remained largely unchanged. In addition, headache intensity, attack duration, acute medication use, disability (HIT-6, MIDAS), and comorbid depression (BDI) and anxiety (BAI) scores all improved. Treatment was well tolerated, with no serious adverse events reported. Conclusion: Galcanezumab was associated with clinically important reduction not only in migraine frequency, severity, disability, and psychological comorbidities, but also in ictal photophobia, highlighting its responsiveness to CGRP-targeted preventive therapy. These findings suggest that photophobia as a potentially modifiable outcome that warrants systematically evaluation in future studies, with larger cohorts and long-term follow-up.

  • Intraoperative Neurophysiologic Monitoring Improves Neurologic Outcomes in Eloquent Brain Areas and Aids in Increasing the Volume of Resected Glioma: Current Results Compared With Historical Controls

    by Elif Ilgaz Aydinlar, Ramazan Sari, Pinar Yalinay Dikmen, İlHan Elmaci

    Purpose: This study aims to show the impact of multimodal intraoperative neurophysiologic monitoring (IOM) in glioma surgery in preventing severe neurologic injury and increasing tumor removal by comparing the historical cases where IOM was not used. Methods: Fifty-nine patients with glial tumors located nearby the eloquent area, operated by the same surgeon, were included in the study. Between 2008 and 2012, 21 patients were operated on without IOM (non-IOM); between 2018 and 2021, 38 patients were operated on with IOM. Results: The preoperative Karnofsky performance status scale (KPSS) scores were not statistically significant between non-IOM and IOM groups (P = 0.351). Postoperative KPSS (mean 97.9) scores were 15.7% higher than preoperative KPSS (mean 84.6) in the IOM group (P < 0.001). Conversely, there was no significant difference between preoperative and postoperative KPSS scores (mean 78.5 and 81.5, respectively) in the non-IOM group (P = 0.472). Moreover, postoperative KPSS scores were 20% higher in the IOM group than in the non-IOM group (P < 0.001). Preoperative tumor sizes were double the size in the non-IOM group compared with those in the IOM group (P = 0.007). Nevertheless, the postsurgery tumor residue volume was almost four times higher in the non-IOM group than that in the IOM group (P = 0.035). A median of 93.35% of the tumor volume was resected in the IOM group, but only 77.26% of the tumor was removed in the non-IOM group (P < 0.001). Conclusions: Intraoperative neurophysiologic monitoring helps in a more radical tumor resection in glial tumors located close to the eloquent area, improves postoperative neurologic outcomes, and maintains the patient's quality of life.


  • Open Access

    The effectiveness and predictors influencing the outcome of onabotulinumtoxinA treatment in chronic migraine: understanding from diverse patient profiles in a single session

    by Elif Ilgaz Aydinlar, Tuba Erdogan Soyukibar, Pinar Yalinay Dikmen

    Objective: This real-world study aimed to investigate how onabotulinumtoxinA affects the outcome of migraine, along with accompanying anxiety, depression, and bruxism among a group of patients with chronic migraine (CM) and define predictors of good response.Methods: Patients diagnosed with CM who received onabotulinumtoxinA were included in this single-center, real-world retrospective cohort study. Monthly headache days (MHDs), monthly migraine days (MMDs), headache intensity (numeric rating scale-NRS) and headache characteristics were evaluated at baseline and 12 weeks post-treatment. Patient-reported outcome measures (PROMs) included Migraine Disability Assessment Scale (MIDAS), Headache Impact Test-6 (HIT-6) scores, 12-item Allodynia Symptom Checklist (ASC-12), Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI). Response to onabotulinumtoxinA (% reduction in MHDs) and treatment-related adverse events (TRAEs) were also evaluated. OnabotulinumA was applied to the masseter muscles in patients complaining of bruxism.Results: A total of 72 patients (mean ± SD age: 36.3 ± 8.5 years; 91.7% were female) diagnosed with CM were included. OnabotulinumtoxinA revealed significant decrease in median (IQR) MHDs [from 20(15–25) at baseline to 6(4–10), p < 0.001], MMDs [from 9(6–12) to 3(1–6), p < 0.001] and NRS [from 9(8–10) to 7(6–8), p < 0.001], and the MIDAS [from 54(30–81) to 16(7–24), p < 0.001], HIT-6 [from 67(65–69) to 58(54–64), p < 0.001], ASC-12 [from 6(1.5–9) to 2(0–9), p = 0.002], BAI [from 12(6.5–19) to 9(3–17), p < 0.001] and BDI [from 11(6.5–17) to 3(2–7) p < 0.001] scores at 12 weeks post-treatment. Patients complaining of bruxism received onabotulinumtoxinA injections in the first n = 27 (37.5%) and 12. week post-treatment n = 19 (70.4%) periods. Overall, 70.8% of patients responded (≥50% reduction in MHDs), while 29.2% did not (<50% reduction). Both groups showed similar characteristics in demographics, migraine history, baseline PROMs scores, comorbidities, and prior treatments.Conclusion: OnabotulinumtoxinA is an effective treatment option that rapidly improves migraine outcomes, disability, and impact while also alleviating comorbid depression and/or anxiety. This study’s noteworthy finding is that onabotulinumtoxinA is effective in a majority of CM patients, irrespective of their prior treatment history, migraine characteristics, or concurrent comorbidities. Furthermore, we identified no specific predictors for a favorable response to onabotulinumtoxinA. Applying onabotulinumtoxinA to the masseter muscles can relieve discomfort associated with concurrent bruxism; however, it does not impact migraine outcomes.


  • Open Access

    Effectiveness of galcanezumab on sleep quality, migraine outcome, and multidimensional patient-reported outcome measures: a real-world experience in Turkish patients with episodic and chronic migraine

    by Elif Ilgaz Aydinlar, Tuba Erdogan Soyukibar, Pinar Yalinay Dikmen

    Introduction: This real-world study aimed to investigate the impact of galcanezumab on sleep quality, migraine outcome and multidimensional patient-reported outcomes measures (PROMs) in patients with episodic migraine (EM) and chronic migraine (CM).Methods: Fifty-four patients with episodic migraine (n = 24) or chronic migraine (n = 30) received a 3-month series of galcanezumab injections and were evaluated for sleep quality, measured using the Pittsburgh Sleep Quality Index (PSQI), as well as migraine outcomes such as monthly headache days (MHDs), monthly migraine days (MMDs), and headache severity. Patient-reported outcome measures (PROMs) such as the Migraine Disability Assessment Scale (MIDAS), Headache Impact Test-6 (HIT-6), SF-36 Health-related Quality of Life (HRQoL), Beck Anxiety Inventory (BAI), and Beck Depression Inventory (BDI) were additionally included in the assessment.Results: The percentage of patients with poor sleep quality (total PSQI scores ≥ 5) was 72.7% at baseline, decreasing to 57.5% and 56.2% at the 1st and 2nd months, respectively. By the 3rd month of galcanezumab injections, significant improvement was observed in the sleep disturbances domain in the overall study population (p = 0.016), and in subgroups of patients with low anxiety levels (p = 0.016) and none/minimal depression (p = 0.035) at baseline. Patients with sleep disorder at baseline exhibited marked improvements in total PSQI scores (p = 0.027) and in the subjective sleep quality (p = 0.034) and daytime dysfunction (p = 0.013) domains, by the 3rd month. Over the 1st, 2nd, and 3rd months, there were significant improvements in MHDs (p < 0.001), MMDs (p < 0.001), HIT-6 scores (p < 0.001 for each), BAI scores (p < 0.001 for each), BDI scores (p ranged from 0.048 to p ranged from 0.012 to <0.001).Conclusion: Galcanezumab demonstrates notable benefits in improving sleep quality, along with a comorbidity-based and domain-specific effect on sleep parameters, which involved sleep disturbances domain in patients without depression or anxiety at baseline but the total PSQI scores, subjective sleep quality and daytime dysfunction in those with sleep disorder at baseline. The treatment also facilitates rapid-onset enhancements in migraine outcomes as well as various PROMs.


  • The adaptation of 12-item Utah Photophobia Symptom Impact Scale (UPSIS-12) in Turkish, internal consistency, and reproducibility

    by Elif Ilgaz Aydınlar, Buse Rahime Hasırcı Bayır, Ozan Dörtkol, Elif Kocasoy Orhan, Esme Ekizoğlu, Betül Baykan, Mustafa Ertaş

    Introduction: The 12-item Utah Photophobia Symptom Impact Scale (UPSIS-12) is a questionnaire to assess the impact of photophobia on daily living during and outside migraine episodes. We aimed to translate UPSIS-12 and assess its usability in the Turkish cohort by analyzing internal consistency, reliability, and reproducibility.Methods: In this multicenter prospective, descriptive study, 120 patients with migraine were recruited. The patients received the diagnosis of migraine without aura (MwoA) and migraine with aura (MwA) according to the International Classification of Headache Disorders 3rd edition. The scale was translated into Turkish, and the patients were evaluated by headache experts in two visits four weeks apart from each other.Results: The questionnaire showed highly correlated test-retest reliability (r=0.828). Cronbach alpha values of internal consistency revealed good to excellent results ranging from 0.78-0.82. There was a strong and positive correlation between self and physician-administered scales at both visits (r=0.964 and 0.985, respectively). The questionnaire was considered "well understood" by 95.6% of the patients. The average UPSIS-12 score of each visit was 25.8 and 26.9 (average standard deviation of 10.4). Subjects with MwoA (25.5 & PLUSMN;10.4) had remarkably lower mean scores compared to MwoA plus MwA (29.2 & PLUSMN;8.9) and MwA (32.9 & PLUSMN;9.4) (p=0.0167). Patients with high frequency migraine presented with a higher mean UPSIS-12 score than those with low frequency (31.3 & PLUSMN;9.5 and 24.7 & PLUSMN;9.8, respectively). It was noted that the mean UPSIS-12 scores of those with severe (29.4 & PLUSMN;9.4) and moderate ictal cutaneous allodynia (CA) (28.4 & PLUSMN;10.6) were higher than those without CA (22.0 & PLUSMN;9.3)(p=0.020).Conclusion: The Turkish version of the UPSIS-12 questionnaire is a reliable tool and well-understood by the Turkish population. Patients with MwA, frequent migraine headache days and moderate to severe CA presented with higher scores. Given the independent burden of photophobia in migraineurs, the use of UPSIS-12 scale should be encouraged in Turkish population.


  • Intraoperative motor speech mapping under general anesthesia using long-latency response from laryngeal muscles

    by Elif Ilgaz Aydinlar, Pinar Yalinay Dikmen, Muge Kocak, Emre Sahillioğlu, M Necmettin Pamir


  • Open Access

    OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study

    by Elif Ilgaz Aydinlar, Pinar Yalinay Dikmen, Seda Kosak, Ayse Sagduyu Kocaman

    OnabotulinumtoxinA (OnabotA) is considered effective in in patients with chronic migraine (CM) who failed on traditional therapies. This study was designed to evaluate the effect of OnabotA injection series on migraine outcome, negative emotional states and sleep quality in patients with CM. A total of 190 patients with CM (mean (SD) age: 39.3 (10.2) years; 87.9% were female) were included. Data on Pittsburgh sleep quality index (PSQI), headache frequency and severity, number of analgesics used, Migraine Disability Assessment Scale. (MIDAS) scores and Depression, Anxiety and Stress Scale (DASS-21) were evaluated at baseline (visit 1) and 4 consecutive follow up visits, each conducted after OnabotA injection series; at week 12 (visit 2), week 24 (visit 3), week 36 (visit 4) and week 48 (visit 5) to evaluate change from baseline to follow up. From baseline to visit 5, significant decrease was noted in least square (LS) mean headache frequency (from 19.5 to 8.4, p = 0.002), headache severity (from 8.1 to 6.1, p = 0.017), number of analgesics (from 26.9 to 10.4, p = 0.023) and MIDAS scores (from 67.3 to 18.5, p < 0.001). No significant change from baseline was noted in global PSOI and DASS-21 scores throughout the study. Our findings revealed that OnabotA therapy was associated with significant improvement in migraine outcome leading to decrease in headache frequency and severity, number of analgesics used and MIDAS scores. While no significant change was noted in overall sleep quality and prevalence of negative emotional states, patients without negative emotional states at baseline showed improved sleep quality throughout the study.